Repligen Corp

RGEN

Company Profile

  • Business description

    Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

  • Contact

    41 Seyon Street
    Building 1, Suite 100
    WalthamMA02453
    USA

    T: +1 781 250-0111

    E: [email protected]

    https://www.repligen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Instruments & Supplies

    Fiscal Year End

    31 December 2026

    Employees

    2,000

Stocks News & Analysis

stocks

Fair value upgrade for this ASX income player

Headwinds in listed energy stocks likely to have passed
stocks

The SpaceX IPO and the Elon Musk factor

Potential investors should remember that the company’s controlling shareholder can move markets with a few words.
stocks

The ASX’s most shorted stocks in 2026

What we can and can’t learn from the top 20 most shorted ASX shares.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,683.9011.500.13%
CAC 407,811.4438.990.50%
DAX 4022,708.86145.980.65%
Dow JONES (US)45,216.1449.500.11%
FTSE 10010,199.2671.300.70%
HKSE24,788.1437.350.15%
NASDAQ20,794.64153.72-0.73%
Nikkei 22551,063.72822.13-1.58%
NZX 50 Index12,912.11163.191.28%
S&P 5006,343.7225.13-0.39%
S&P/ASX 2008,481.804.600.05%
SSE Composite Index3,891.8631.43-0.80%

Market Movers